최소 단어 이상 선택하여야 합니다.
최대 10 단어까지만 선택 가능합니다.
다음과 같은 기능을 한번의 로그인으로 사용 할 수 있습니다.
NTIS 바로가기Journal of obesity & metabolic syndrome, v.30 no.3, 2021년, pp.196 - 208
Ryan, Donna H. (Pennington Biomedical Research Center, Baton Rouge, LA, USA)
There is a new generation of antiobesity drugs in development or just arriving on the scene. First, setmelanotide has been approved for three of the ultrarare genetic conditions that cause obesity–pro-opiomelanocortin deficiency, proprotein convertase subtilisin and kexin type 1 (an important...
1 Sharma S Garfield AS Shah B Kleyn P Ichetovkin I Moeller IH 2019 Current mechanistic and pharmacodynamic understanding of melanocortin-4 receptor activation Molecules 24 1892 10.3390/molecules24101892 31100979
2 Kievit P Halem H Marks DL Dong JZ Glavas MM Sinnayah P 2013 Chronic treatment with a melanocortin-4 receptor agonist causes weight loss, reduces insulin resistance, and improves cardiovascular function in diet-induced obese rhesus macaques Diabetes 62 490 7 10.2337/db12-0598 23048186
3 Collet TH Dubern B Mokrosinski J Connors H Keogh JM Mendes de Oliveira E 2017 Evaluation of a melanocortin-4 receptor (MC4R) agonist (Setmelanotide) in MC4R deficiency Mol Metab 6 1321 9 10.1016/j.molmet.2017.06.015 29031731
4 Kühnen P Clément K Wiegand S Blankenstein O Gottesdiener K Martini LL 2016 Proopiomelanocortin deficiency treated with a melanocortin-4 receptor agonist N Engl J Med 375 240 6 10.1056/NEJMoa1512693 27468060
5 Haws R Brady S Davis E Fletty K Yuan G Gordon G 2020 Effect of setmelanotide, a melanocortin-4 receptor agonist, on obesity in Bardet-Biedl syndrome Diabetes Obes Metab 22 2133 40 10.1111/dom.14133 32627316
6 Ayers KL Glicksberg BS Garfield AS Longerich S White JA Yang P 2018 Melanocortin 4 receptor pathway dysfunction in obesity: patient stratification aimed at MC4R agonist treatment J Clin Endocrinol Metab 103 2601 12 10.1210/jc.2018-00258 29726959
7 Clément K Biebermann H Farooqi IS Van der Ploeg L Wolters B Poitou C 2018 MC4R agonism promotes durable weight loss in patients with leptin receptor deficiency Nat Med 24 551 5 10.1038/s41591-018-0015-9 29736023
8 Wikimedia Commons Contributors 2020 "File:Setmelanotide.svg [Internet] Wikimedia Commons, the free media repository Available from: https://commons.wikimedia.org/w/index.php?title=File:Setmelanotide.svg&oldid=467575939 cited 2021 Sep 17
9 Echemi 2020 Lilly's GLP-1 and Tirzepatide initiates phase III clinical trial [Internet] Echemi Available from: https://www.echemi.com/cms/110494.html cited 2021 Sep 17
10 RCSB Protein Data Bank 2017 Biological assembly 1 of bimagrumab [Internet] RCSB Protein Data Bank Available from: https://www.rcsb.org/structure/5nhw cited 2021 Sep 17
11 U.S. Food and Drug Administration 2020 FDA approves first treatment for weight management for people with certain rare genetic conditions [Internet] U.S. Food and Drug Administration Silver Spring (MD) Available from: https://www.fda.gov/drugs/drug-safety-and-availability/fda-approves-first-treatment-weight-management-people-certain-rare-genetic-conditions cited 2021 Mar 18
12 BioWorld 2020 Rhythm wins first FDA approval for obesity drug Imcivree [Internet] BioWorld Available from: https://www.bioworld.com/articles/500740-rhythm-wins-first-fda-approval-for-obesity-drug-imcivree?v=preview cited 2021 Mar 18
13 Clément K van den Akker E Argente J Bahm A Chung WK Connors H 2020 Efficacy and safety of setmelanotide, an MC4R agonist, in individuals with severe obesity due to LEPR or POMC deficiency: single-arm, open-label, multicentre, phase 3 trials Lancet Diabetes Endocrinol 8 960 70 10.1016/S2213-8587(20)30364-8 33137293
14 Ayers KL Glicksberg BS Garfield AS Longerich S White JA Yang P 2018 Melanocortin 4 receptor pathway dysfunction in obesity: patient stratification aimed at MC4R agonist treatment J Clin Endocrinol Metab 103 2601 12 10.1210/jc.2018-00258 29726959
16 Ryan D Acosta A 2015 GLP-1 receptor agonists: nonglycemic clinical effects in weight loss and beyond Obesity (Silver Spring) 23 1119 29 10.1002/oby.21107 25959380
17 Marso SP Bain SC Consoli A Eliaschewitz FG Jódar E Leiter LA 2016 Semaglutide and cardiovascular outcomes in patients with type 2 diabetes N Engl J Med 375 1834 44 10.1056/NEJMoa1607141 27633186
18 O'Neil PM Birkenfeld AL McGowan B Mosenzon O Pedersen SD Wharton S 2018 Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: a randomised, double-blind, placebo and active controlled, dose-ranging, phase 2 trial Lancet 392 637 49 10.1016/S0140-6736(18)31773-2 30122305
19 Kushner RF Calanna S Davies M Dicker D Garvey WT Goldman B 2020 Semaglutide 2.4 mg for the treatment of obesity: key elements of the STEP trials 1 to 5 Obesity (Silver Spring) 28 1050 61 10.1002/oby.22794 32441473
20 Wilding JP Batterham RL Calanna S Davies M Van Gaal LF Lingvay I 2021 Once-weekly semaglutide in adults with overweight or obesity N Engl J Med 384 989 1002 10.1056/NEJMoa2032183 33567185
21 Davies M Færch L Jeppesen OK Pakseresht A Pedersen SD Perreault L 2021 Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial Lancet 397 971 84 10.1016/S0140-6736(21)00213-0 33667417
22 Wadden TA Bailey TS Billings LK Davies M Frias JP Koroleva A 2021 Effect of Subcutaneous semaglutide vs placebo as an adjunct to intensive behavioral therapy on body weight in adults with overweight or obesity: the STEP 3 randomized clinical trial JAMA 325 1403 13 10.1001/jama.2021.1831 33625476
23 Rubino D Abrahamsson N Davies M Hesse D Greenway FL Jensen C 2021 Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity: the STEP 4 randomized clinical trial JAMA 325 1414 25 10.1001/jama.2021.3224 33755728
24 Wadden TA West DS Delahanty L Jakicic J Rejeski J Look AHEAD Research Group 2006 The Look AHEAD study: a description of the lifestyle intervention and the evidence supporting it Obesity (Silver Spring) 14 737 52 10.1038/oby.2006.84 16855180
25 Heymsfield SB Gonzalez MC Shen W Redman L Thomas D 2014 Weight loss composition is one-fourth fat-free mass: a critical review and critique of this widely cited rule Obes Rev 15 310 21 10.1111/obr.12143 24447775
26 Wing RR Look AHEAD Research Group 2021 Does lifestyle intervention improve health of adults with overweight/obesity and type 2 diabetes? Findings from the look AHEAD randomized trial Obesity (Silver Spring) 29 1246 58 10.1002/oby.23158 33988896
27 Pilitsi E Farr OM Polyzos SA Perakakis N Nolen-Doerr E Papathanasiou AE 2019 Pharmacotherapy of obesity: available medications and drugs under investigation Metabolism 92 170 92 10.1016/j.metabol.2018.10.010 30391259
28 Ryan DH Lingvay I Colhoun HM Deanfield J Emerson SS Kahn SE 2020 Semaglutide Effects on Cardiovascular Outcomes in People With Overweight or Obesity (SELECT) rationale and design Am Heart J 229 61 9 10.1016/j.ahj.2020.07.008 32916609
29 Ryan DH Yockey SR 2017 Weight loss and improvement in comorbidity: differences at 5%, 10%, 15%, and over Curr Obes Rep 6 187 94 10.1007/s13679-017-0262-y 28455679
30 Magkos F Fraterrigo G Yoshino J Luecking C Kirbach K Kelly SC 2016 Effects of moderate and subsequent progressive weight loss on metabolic function and adipose tissue biology in humans with obesity Cell Metab 23 591 601 10.1016/j.cmet.2016.02.005 26916363
31 Friedrichsen M Breitschaft A Tadayon S Wizert A Skovgaard D 2021 The effect of semaglutide 2.4 mg once weekly on energy intake, appetite, control of eating, and gastric emptying in adults with obesity Diabetes Obes Metab 23 754 62 10.1111/dom.14280 33269530
32 Frias JP Nauck MA Van J Kutner ME Cui X Benson C 2018 Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial Lancet 392 2180 93 10.1016/S0140-6736(18)32260-8 30293770
33 ClinicalTrial.gov 2019 A study of tirzepatide (LY3298176) in participants with obesity or overweight (SURMOUNT-1) [Internet] U.S. National Library of Medicine Bethesda (MD) Available from: https://clinicaltrials.gov/ct2/show/NCT04184622 cited 2021 Mar 18
34 Min T Bain SC 2021 The role of tirzepatide, dual GIP and GLP-1 receptor agonist, in the management of type 2 diabetes: the SURPASS clinical trials Diabetes Ther 12 143 57 10.1007/s13300-020-00981-0 33325008
35 Eli Lilly and Company 2021 Tirzepatide achieved superior A1C and body weight reductions across all three doses compared to injectable semaglutide in adults with type 2 diabetes [Internet] Lilly Indianapolis (IL) Available from: Investor.lilly.com/news-releases/news-releasedetails/tirzepatide-achieved-superior-a1c-and-body-weight-reductions
36 Fournier B Murray B Gutzwiller S Marcaletti S Marcellin D Bergling S 2012 Blockade of the activin receptor IIb activates functional brown adipogenesis and thermogenesis by inducing mitochondrial oxidative metabolism Mol Cell Biol 32 2871 9 10.1128/MCB.06575-11 22586266
37 Rooks DS Laurent D Praestgaard J Rasmussen S Bartlett M Tankó LB 2017 Effect of bimagrumab on thigh muscle volume and composition in men with casting-induced atrophy J Cachexia Sarcopenia Muscle 8 727 34 10.1002/jcsm.12205 28905498
38 Heymsfield SB Coleman LA Miller R Rooks DS Laurent D Petricoul O 2021 Effect of bimagrumab vs placebo on body fat mass among adults with type 2 diabetes and obesity: a phase 2 randomized clinical trial JAMA Netw Open 4 e2033457 10.1001/jamanetworkopen.2020.33457 33439265
39 Srivastava G Apovian C 2018 Future pharmacotherapy for obesity: new anti-obesity drugs on the horizon Curr Obes Rep 7 147 61 10.1007/s13679-018-0300-4 29504049
40 Rebello CJ Greenway FL 2020 Obesity medications in development Expert Opin Investig Drugs 29 63 71 10.1080/13543784.2020.1705277 31847611
※ AI-Helper는 부적절한 답변을 할 수 있습니다.